Kathleen M. Schmainda1,2, Devyani Bedekar1,2, Scott D. Rand1,2, Jennifer Connelly, 23, Mark Malkin, 23
1Radiology, Medical College of Wisconsin, Milwaukee, WI, United States; 2Translational Brain Tumor Research Program, Medical College of Wisconsin, Milwaukee, WI, United States; 3Neurology, Medical College of Wisconsin, Milwaukee, WI, United States
The prognosis for patients diagnosed with brain tumors has been dismal. Now there is hope with improved time to progression and survival noted for patients treated with anti-angiogenic drugs such as bevacizumab. Yet, many questions remain regarding the appropriate selection of patients most likely to respond. These questions are important from both a clinical and economic perspective and therefore speak to the need for ways to efficiently and reliably predict response. Here we demonstrate the potential of DSC-measures of rCBV, obtained just prior to treatment with bevacizumab, to predict outcomes in patients with both new and recurrent GBM.